In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers remains a challenge for most clinicians. Up to 40% of patients with DLBCL do not respond to first line (1L) treatments, necessitating a search for new targets beyond CD20. New therapies are being explored in the treatment of DLBCL with a focus on more targeted and personalized treatments. Despite an array of new options, there is currently no established optimal sequence of drugs or consensus on the best order of administration, highlighting the need for further education. In this CE Concepts Grand Rounds series, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL.
- Provider:Creative Educational Concepts, Inc.
- Activity Link: https://www.ceconcepts.com/activity/all-hands-on-deck-spotlight-on-clinical-advances-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-2/
- Start Date: 2025-02-06 06:00:00
- End Date: 2025-02-06 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Medical Oncology